EU quality system requirements for drugs and biologics
An organisation that manufactures a medicinal product for human use within a Member State must hold a manufacturing authorisation granted under Title IV of Directive 2001/83/EC, and must operate under the principles and guidelines of good manufacturing practice. The obligation attaches to the operation itself. It applies from the moment total or partial manufacture, dividing up, packaging or presentation is carried out in the territory, and it applies equally to import from a third country.1
When the authorisation requirement attaches
Article 40(1) requires Member States to ensure that manufacture of medicinal products within their territory is subject to the holding of an authorisation. That authorisation is required even where the products manufactured are intended for export.1 The trigger is the manufacturing operation and the place where it happens. The text of Article 40 does not condition the requirement on the existence of a marketing authorisation for the product concerned.
Article 40(2) extends the requirement to both total and partial manufacture, and to the various processes of dividing up, packaging or presentation. A contract packer or a site performing a single unit operation therefore falls within the same regime as a site running a full synthesis or fill and finish line.1 One derogation appears in the same paragraph. Authorisation is not required for preparation, dividing up or changes in packaging or presentation where those processes are carried out solely for retail supply by pharmacists in dispensing pharmacies or by persons legally authorised in the Member State to carry them out.1
Article 40(3) provides that the authorisation is also required for imports coming from third countries into a Member State. Title IV and Article 118 apply to such imports as they apply to manufacture.1 An importer of finished product from outside the Union operates under the same licensing and quality obligations as a manufacturer inside it.
Member States enter the information relating to each manufacturing authorisation in the Union database referred to in Article 111(6).1
What the applicant must have in place
Article 41 sets out the minimum conditions for obtaining a manufacturing authorisation. The applicant must specify the medicinal products and pharmaceutical forms to be manufactured or imported, together with the place where they are to be manufactured or controlled.1 The authorisation is therefore tied to named products, named dosage forms and named premises from the outset.
The applicant must have at its disposal suitable and sufficient premises, technical equipment and control facilities. Those facilities must comply with the legal requirements the Member State concerned lays down for manufacture, control and storage of medicinal products, in accordance with Article 20.1 The applicant must also have at its disposal the services of at least one qualified person within the meaning of Article 48.1 Particulars in support of each of these points are supplied with the application.
Article 41 states these as requirements the applicant must meet “at least”. Member States may impose further conditions under their own law on manufacture and control.
Continuing obligations of the authorisation holder
Article 46 lists the obligations that run for as long as the authorisation is held. The holder must have at its disposal the services of staff who comply with the legal requirements of the Member State concerned as regards manufacture and controls.1 Authorised medicinal products may be disposed of only in accordance with the legislation of the Member States concerned.1
Changes to the particulars supplied under Article 41 require prior notice to the competent authority. Where the qualified person is replaced unexpectedly, the competent authority must be informed immediately.1 The holder must allow agents of the competent authority access to its premises at any time, and must enable the qualified person to carry out the duties in Article 51, for example by placing the necessary facilities at that person’s disposal.1
Article 46(g) covers falsified products. The holder must inform the competent authority and the marketing authorisation holder immediately on obtaining information that products within the scope of its manufacturing authorisation are, or are suspected of being, falsified. That duty applies whether the products were distributed within the legal supply chain or by illegal means, including illegal sale by means of information society services.1
Control over active substances and excipients
Article 46(f) is the core quality obligation. The holder must comply with the principles and guidelines of good manufacturing practice for medicinal products. It must use only active substances manufactured in accordance with good manufacturing practice for active substances and distributed in accordance with good distribution practices for active substances.1
Verification of that compliance is an audit obligation. The holder must verify compliance by the manufacturer and the distributors of active substances by conducting audits at their manufacturing and distribution sites. The audits may be performed by the holder or by an entity acting on its behalf under a contract, and use of a contracted entity does not displace the holder’s own responsibility under the Directive.1
Excipients are handled through a documented risk assessment rather than an automatic good manufacturing practice standard. The holder must ensure that excipients are suitable for use in medicinal products by ascertaining what the appropriate good manufacturing practice is. That determination rests on a formalised risk assessment made in accordance with the guidelines referred to in the fifth paragraph of Article 47. The assessment takes into account requirements under other appropriate quality systems, the source and intended use of the excipient and previous instances of quality defects.1 The holder must then apply the good manufacturing practice so ascertained and must document the measures taken.1
Two further checks sit alongside. The holder must verify that the manufacturers, importers or distributors from whom it obtains active substances are registered with the competent authority of the Member State where they are established. It must also verify the authenticity and quality of the active substances and the excipients.1
Where the detailed standards come from
Article 47 separates the instruments that carry the detail. Article 121a gives the Commission the power to adopt delegated acts specifying the principles and guidelines of good manufacturing practice for medicinal products referred to in Article 46(f).1 Detailed guidelines in line with those principles are published by the Commission and revised to take account of technical and scientific progress.1
For active substances, the principles and guidelines of good manufacturing practice referred to in Article 46(f) and Article 46b are adopted by delegated act under Article 121a, subject to the conditions in Articles 121b and 121c.1 The principles of good distribution practices for active substances are adopted in the form of guidelines.1 The Commission also adopts guidelines on the formalised risk assessment used to determine the appropriate good manufacturing practice for excipients.1 The distinction matters when assessing what binds directly and what states the Commission’s expectation.
Batch certification by the qualified person
Article 51 places batch release in the hands of a named individual. For products manufactured within the Member State concerned, the qualified person is responsible for securing that each batch has been manufactured and checked in compliance with the laws in force in that Member State and in accordance with the requirements of the marketing authorisation.1 The responsibility exists without prejudice to that person’s relationship with the authorisation holder.
For products coming from third countries, the standard is heavier. Each production batch must have undergone in a Member State a full qualitative analysis, a quantitative analysis of at least all the active substances and all other tests or checks necessary to ensure quality in accordance with the marketing authorisation. That applies irrespective of whether the product was manufactured in the Community.1 The Union regime requires the analysis to be repeated within a Member State, even where another system would accept testing at the foreign site.
Two reliefs exist. Batches that have undergone the controls in one Member State are exempt from the controls when marketed in another, provided they are accompanied by control reports signed by the qualified person.1 Under Article 51(2), where appropriate arrangements have been made by the Community with an exporting country covering equivalent good manufacturing practice standards and the carrying out of the Article 51(1)(b) controls in that country, the qualified person may be relieved of responsibility for carrying out those controls.1
For products intended to be placed on the market in the Union, the qualified person must ensure that the safety features referred to in Article 54(o) have been affixed on the packaging.1
Certification is a record obligation as well as a decision. Article 51(3) requires the qualified person to certify in a register or equivalent document that each production batch satisfies the Article. The register must be kept up to date as operations are carried out and must remain at the disposal of the agents of the competent authority for the period specified by the Member State, and in any event for at least five years.1
Imports into Northern Ireland
Article 40(1a) allows the competent authorities of the United Kingdom in respect of Northern Ireland to permit import of medicinal products from parts of the United Kingdom other than Northern Ireland by holders of a wholesale distribution authorisation under Article 77(1) without a manufacturing authorisation. All the listed conditions must be met. They cover quality control testing, batch release by a qualified person applying the standards of Article 51(1) and a marketing authorisation granted in accordance with Union law or by the United Kingdom authority for Northern Ireland. They also cover supply limited to patients or end consumers in the importing territory and the presence of the safety features in Article 54(o).1 The equivalent derogation for the competent authorities of Cyprus, Ireland and Malta ran until 31 December 2024.1
Article 40(3a) removes the importation controls in the first and second subparagraphs of Article 51(1) for batches exported from a Member State to parts of the United Kingdom other than Northern Ireland and subsequently imported into Northern Ireland. The batches must have undergone those controls in a Member State before export and must be accompanied by the control reports referred to in the third subparagraph of Article 51(1).1 The same relief applied to imports into Cyprus, Ireland and Malta until 31 December 2024.1
Questions people also ask
Does a site that only packages a finished medicinal product need a manufacturing authorisation?
Yes. Article 40(2) states that the authorisation is required for both total and partial manufacture and for the various processes of dividing up, packaging or presentation. The only carve-out in that paragraph covers preparation, dividing up and changes in packaging or presentation carried out solely for retail supply by pharmacists in dispensing pharmacies or by other persons legally authorised in the Member State.1
Is a manufacturing authorisation needed where the product is made only for export?
Yes. Article 40(1) states that the manufacturing authorisation is required notwithstanding that the medicinal products manufactured are intended for export.1 The destination of the product does not change the licensing position of the site.
Must batches imported from outside the Union be tested again in a Member State?
Article 51(1)(b) requires that each production batch coming from a third country has undergone in a Member State a full qualitative analysis, a quantitative analysis of at least all the active substances and all other tests or checks needed to meet the marketing authorisation. Article 51(2) allows the qualified person to be relieved of that responsibility where the Community has made appropriate arrangements with the exporting country on equivalent good manufacturing practice standards and on the carrying out of those controls there.1
How long must batch certification records be retained?
Article 51(3) requires the register or equivalent document to remain at the disposal of the agents of the competent authority for the period specified by the Member State concerned, and in any event for at least five years.1 The register must be kept up to date as operations are carried out.
What must an authorisation holder do about its active substance suppliers?
Article 46(f) requires the holder to use only active substances manufactured under good manufacturing practice for active substances and distributed under good distribution practices, and to verify that compliance by auditing the manufacturing and distribution sites. Article 46(h) requires verification that the manufacturers, importers or distributors of active substances are registered with the competent authority of the Member State where they are established. Article 46(i) requires verification of the authenticity and quality of active substances and excipients.1
When must a competent authority be told that the qualified person has changed?
Article 46(c) requires prior notice of any changes the holder wishes to make to the particulars supplied under Article 41. Where the qualified person referred to in Article 48 is replaced unexpectedly, the competent authority must be informed immediately.1
Footnotes
-
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Consolidated version of 2025-01-01. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02001L0083-20250101 ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23 ↩24 ↩25 ↩26 ↩27 ↩28 ↩29 ↩30 ↩31 ↩32 ↩33 ↩34 ↩35 ↩36 ↩37 ↩38 ↩39 ↩40
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.